Asthma is the most common chronic respiratory disease of childhood with prevalence, morbidity and mortality increasing in epidemic proportions throughout the world despite better diagnosis and improved anti-inflammatory treatment. Recombinant humanized monoclonal anti-IgE is the most promising immunomodulatory agent available today to non-specifically modulate IgE, the major effector molecule in allergic asthma. Anti-IgE reduces free IgE and IgE receptors more than 95 percent, improves asthma symptoms, lung function, and reduces prn bronchodilator use and corticosteroid use in moderate to severe persistent allergic asthma in adolescents and adults. Proposed here are two projects, each prospective, randomized, masked, and placebo-controlled, to evaluate the effectiveness and safety of anti-IgE in primary and secondary asthma prevention in children. Proposal number 1 or primary asthma prevention will determine whether anti-IgE can prevent the development of asthma in 232 high-risk infants 1 to 2 years of age with atopic dermatitis, food allergy, or allergic rhinitis and specific IgE and a parental history of atopy. Patients will be randomized into anti-IgE or placebo groups, given bimonthly subcutaneous injections of anti-IgE or placebo, and followed for the development of asthma for 3 years. Secondary objectives include determination if anti-IgE compared to placebo differ with respect to (1) the onset of at least mild persistent asthma, (2) lung impedance and bronchial responsiveness determined by impulse oscillation, (3) skin test reactivity and markers of inflammation, (4) effect on atopic disorders, and (5) long-term safety and growth. Proposal number 2 or secondary asthma prevention will determine the effectiveness of anti-IgE compared to placebo to reduce inhaled corticosteroid (ICS) requirements (steroid sparing) in 140 children 5-12 years of age with moderate to severe persistent allergic asthma requiring ICS. Subjects will be randomized into anti-IgE or placebo groups, given bimonthly subcutaneous injections of anti-IgE or placebo for 1 year, and followed in two phases. During Phase I or the 12-week adjunctive phase, patients will maintain their stable dose of ICS, and during Phase II or the 40-week ICS withdrawal phase, subjects will have their ICS reduced according to protocol. The efficacy and safety of anti- IgE therapy versus placebo will be compared in terms of (1) the reduction in ICS dose measured by real time monitoring of ICS use electronically (primary aim), (2) asthma symptom scores, medication use, and peak expiratory flow levels monitored electronically, (3) levels of lung function and bronchial responsiveness, (4) humanistic and pharmacoeconomic measures, (6) skin test reactivity and markers of inflammation, (7) somatic growth, and (8) adverse events.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10HL064295-02
Application #
6184633
Study Section
Special Emphasis Panel (ZHL1-CSR-H (S1))
Project Start
1999-09-30
Project End
2004-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
2
Fiscal Year
2000
Total Cost
$639,248
Indirect Cost
Name
University of California San Diego
Department
Pediatrics
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Beigelman, Avraham; Bacharier, Leonard B (2016) Management of Preschool Children with Recurrent Wheezing: Lessons from the NHLBI's Asthma Research Networks. J Allergy Clin Immunol Pract 4:1-8; quiz 9-10
Israel, Elliot; Lasky-Su, Jessica; Markezich, Amy et al. (2015) Genome-wide association study of short-acting ?2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3. Am J Respir Crit Care Med 191:530-7
Gerald, Joe K; Gerald, Lynn B; Vasquez, Monica M et al. (2015) Markers of Differential Response to Inhaled Corticosteroid Treatment Among Children with Mild Persistent Asthma. J Allergy Clin Immunol Pract 3:540-6.e3
Beigelman, Avraham; Zeiger, Robert S; Mauger, David et al. (2014) The association between vitamin D status and the rate of exacerbations requiring oral corticosteroids in preschool children with recurrent wheezing. J Allergy Clin Immunol 133:1489-92, 1492.e1-3
Rabinovitch, Nathan; Mauger, David T; Reisdorph, Nichole et al. (2014) Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma. J Allergy Clin Immunol 133:350-6
Beigelman, Avraham; Zeiger, Robert S; Kelly, H William et al. (2014) The challenge of treating preschool wheezing episodes: the need for evidence-based approaches. J Allergy Clin Immunol 133:1016-7
Malka, Jonathan; Mauger, David T; Covar, Ronina et al. (2014) Eczema and race as combined determinants for differential response to step-up asthma therapy. J Allergy Clin Immunol 134:483-5
Chang, Timothy S; Lemanske Jr, Robert F; Mauger, David T et al. (2014) Childhood asthma clusters and response to therapy in clinical trials. J Allergy Clin Immunol 133:363-9
Himes, Blanca E; Sheppard, Keith; Berndt, Annerose et al. (2013) Integration of mouse and human genome-wide association data identifies KCNIP4 as an asthma gene. PLoS One 8:e56179
Himes, Blanca E; Qiu, Weiliang; Klanderman, Barbara et al. (2013) ITGB5 and AGFG1 variants are associated with severity of airway responsiveness. BMC Med Genet 14:86

Showing the most recent 10 out of 38 publications